Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou
{"title":"[End of COBE2991®: What alternatives are available for the preparation of each type of cell therapy products? (SFGM-TC)].","authors":"Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou","doi":"10.1016/j.bulcan.2025.04.008","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this article is to discuss alternatives to COBE2991® (Terumo BCT©) for the preparation of cell therapy products, in view of its planned cessation of commercialization in 2025. Cell therapy units need to find alternative methods in the face of regulatory restrictions and equipment obsolescence. Currently, COBE2991® (Terumo BCT©) is widely used in France, but its replacement will require multiple validations and adjustment of practices, as there is no single equivalent equipment. Recommendations for harmonizing these practices were discussed at a specific workshop in September 2024, following a survey of 25 French-speaking cell therapy centers.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2025.04.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this article is to discuss alternatives to COBE2991® (Terumo BCT©) for the preparation of cell therapy products, in view of its planned cessation of commercialization in 2025. Cell therapy units need to find alternative methods in the face of regulatory restrictions and equipment obsolescence. Currently, COBE2991® (Terumo BCT©) is widely used in France, but its replacement will require multiple validations and adjustment of practices, as there is no single equivalent equipment. Recommendations for harmonizing these practices were discussed at a specific workshop in September 2024, following a survey of 25 French-speaking cell therapy centers.
[COBE2991®结束：每种类型的细胞治疗产品的制备有哪些替代品？](SFGM-TC)]。
鉴于COBE2991®（Terumo BCT©）计划于2025年停止商业化，本文的目的是讨论用于制备细胞治疗产品的COBE2991®的替代品。细胞治疗单位需要寻找替代方法，面对监管限制和设备陈旧。目前，COBE2991®（Terumo BCT©）在法国广泛使用，但其替换将需要多次验证和调整实践，因为没有单一的等效设备。在对25个讲法语的细胞治疗中心进行调查后，在2024年9月的一个专门研讨会上讨论了协调这些做法的建议。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
